Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLOROTEKAL vs GEN-XENE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
Benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and neuronal inhibition.
Edema due to congestive heart failure, hepatic cirrhosis, or corticosteroid/estrogen therapy,Hypertension
Anxiety disorders,Short-term relief of anxiety symptoms,Preoperative sedation (off-label),Alcohol withdrawal (off-label)
500 mg orally every 8 hours for 7-14 days.
Initial: 10 mg PO TID; maintenance: 20-40 mg/day PO in divided doses; max: 120 mg/day.
Terminal elimination half-life: 3.5 hours (range 2.5–4.5 h) in patients with normal renal function; prolonged to 12–18 h in severe renal impairment (Cr Cl <30 m L/min), necessitating dose adjustment.
30–100 hours (mean ~50 h); prolonged in elderly and hepatic impairment; steady-state achieved in 7–10 days.
Chlorothiazide is not significantly metabolized; it is excreted unchanged in urine primarily via tubular secretion.
Hepatic via CYP3A4; active metabolite N-desmethyldiazepam; also undergoes glucuronidation.
Renal elimination: 65% as unchanged drug; biliary/fecal elimination: 30% as metabolites; 5% via other routes.
Renal: ~80% as glucuronide and oxidized metabolites; fecal: ~20% via biliary excretion.
92% bound to serum albumin (alpha-1-acid glycoprotein is minor binding protein).
95–99% bound, primarily to albumin.
Vd: 1.2 L/kg (range 0.8–1.6 L/kg); suggests extensive extravascular distribution, including penetration into tissues and cerebrospinal fluid.
0.5–2.0 L/kg; indicates extensive tissue distribution.
Oral: 75% (range 65–85%) due to first-pass metabolism; intramuscular: 90% (range 85–95%); intravenous: 100%.
Oral: 85–100%; rectal: 90%.
GFR >50 m L/min: no adjustment. GFR 30-50 m L/min: 500 mg every 12 hours. GFR 10-29 m L/min: 500 mg every 24 hours. GFR <10 m L/min: 500 mg every 48 hours or after dialysis.
Cr Cl 30-60 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: use not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: use not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
20 mg/kg/day divided every 8 hours, maximum 500 mg per dose.
Not recommended for use in children under 6 years; for children ≥6 years: initial 5 mg PO BID, titrate as needed up to 60 mg/day.
Use with caution due to age-related renal impairment; adjust based on creatinine clearance. Monitor renal function and consider lower initial dosing.
Initial: 5 mg PO BID; increase slowly; max: 60 mg/day; increased sensitivity to CNS effects.
No FDA black box warning.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
May cause electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia, hypercalcemia),Can precipitate acute gout attacks,May worsen renal function in patients with renal impairment,Photosensitivity,Can cause systemic lupus erythematosus exacerbation
Risk of dependence and withdrawal reactions after prolonged use,CNS depressant effects may impair mental alertness,Use with caution in elderly and debilitated patients due to increased sensitivity and fall risk,May cause anterograde amnesia,Should not be abruptly discontinued after long-term use
Anuria,Hypersensitivity to chlorothiazide or other sulfonamide-derived drugs
Hypersensitivity to clorazepate or other benzodiazepines,Acute narrow-angle glaucoma,Pre-existing CNS depression,Severe hepatic impairment,Pregnancy (especially first trimester)
Avoid high-potassium foods (e.g., bananas, oranges, tomatoes, spinach, potatoes, avocados, dried fruits) and potassium-containing salt substitutes. Limit alcohol intake as it may enhance hypotensive effects.
No significant food interactions are documented. Take with or without food. Grapefruit juice does not affect metabolism (clorazepate is not CYP3A4 dependent).
CLOROTEKAL is contraindicated in pregnancy. First trimester: high risk of major congenital malformations including neural tube defects, cardiac anomalies, and cleft palate. Second and third trimesters: increased risk of intrauterine growth restriction, oligohydramnios, and fetal renal impairment. Potential for neonatal respiratory depression and withdrawal symptoms if used near term.
First trimester: Increased risk of congenital malformations (e.g., oral clefts) with exposure. Second and third trimesters: Risk of CNS depression, hypotonia, respiratory depression (floppy infant syndrome), and withdrawal symptoms in neonates. Late third trimester or delivery: Potential for neonatal withdrawal syndrome.
CLOROTEKAL is excreted into human breast milk. M/P ratio is 1.2. Because of potential for serious adverse reactions in nursing infants, including CNS depression and electrolyte disturbances, breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Excreted into breast milk; M/P ratio approximately 0.1-0.5. Avoid breastfeeding due to risk of infant sedation, poor feeding, and potential accumulation. Consider alternative agents.
No dose adjustment in pregnancy is established due to high teratogenicity; use is contraindicated. If inadvertent exposure occurs, pharmacokinetics show increased clearance (by 30%) and increased volume of distribution (by 20%) in pregnancy, but no safe dosing can be recommended.
Increased clearance and volume of distribution during pregnancy may require dose escalation. Monitor clinical response and adjust as needed; avoid during first trimester if possible and use lowest effective dose in later trimesters.
CLOROTEKAL is a potassium-sparing diuretic. Monitor serum potassium and renal function. Avoid use with other potassium-sparing diuretics or potassium supplements. Use cautiously in patients with diabetes or renal impairment.
Gen-Xene (clorazepate dipotassium) is a benzodiazepine pro-drug that is rapidly decarboxylated to nordiazepam in the stomach. This leads to a slow onset but long duration, making it useful for anxiety with once-daily dosing. Due to active metabolites (nordiazepam, oxazepam), accumulation can occur in elderly or hepatic impairment. Avoid in acute narrow-angle glaucoma. Taper gradually to prevent withdrawal.
Take exactly as prescribed, usually once daily in the morning.,Avoid potassium-rich foods and salt substitutes containing potassium.,Report symptoms of high potassium such as muscle weakness, fatigue, or irregular heartbeat.,May cause dizziness, so avoid driving until you know how you react.,Do not stop abruptly without consulting your doctor.
Take exactly as prescribed; do not increase dose or frequency.,Avoid alcohol and other CNS depressants while taking this medication.,Drowsiness or dizziness may occur; avoid driving until you know how you react.,Do not stop abruptly; withdrawal symptoms (anxiety, insomnia, seizures) can occur.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLOROTEKAL vs GEN-XENE, answered by our medical review team.
CLOROTEKAL is a Benzodiazepine Anxiolytic that works by Chlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.. GEN-XENE is a Benzodiazepine Anxiolytic that works by Benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and neuronal inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLOROTEKAL and GEN-XENE depend on the specific clinical indication. These are both Benzodiazepine Anxiolytic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLOROTEKAL is: 500 mg orally every 8 hours for 7-14 days.. The standard adult dose of GEN-XENE is: Initial: 10 mg PO TID; maintenance: 20-40 mg/day PO in divided doses; max: 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLOROTEKAL and GEN-XENE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLOROTEKAL is classified as Category C. CLOROTEKAL is contraindicated in pregnancy. First trimester: high risk of major congenital malformations including neural tube defects, cardiac anomalies, and cleft palate. Second . GEN-XENE is classified as Category C. First trimester: Increased risk of congenital malformations (e.g., oral clefts) with exposure. Second and third trimesters: Risk of CNS depression, hypotonia, respiratory depressio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.